ArticleJournal of nanobiotechnology2025
Apoptotic vesicles rectify senile bone-fat imbalance by activating Thy1-ERK-TAZ axis.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Stem Cell-Derived Extracellular Vesicles for the Treatment of Osteoporosis: A Systematic Review of Preclinical Evidence.Biomedicines · 2026Review
- Apoptosis of Mdm2-deficient osteocytes enhances osteogenesis through TRPM8-enriched apoptotic vesicles.Bone research · 2026Article
- Early-apoptotic membrane engineering of M2 macrophage-derived nanovesicles enables osteoimmunomodulatory bone repair.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSenile bone-fat imbalance poses a significant public health burden in aging populations. This study investigates how aging affects the heterogeneity of mesenchymal stem cell (MSC)-derived apoptotic vesicles (apoVs) and develops a therapeutic strategy to rectify age-related bone-fat metabolic disorders.
resultsProtein cargo analysis revealed that MSC-derived apoVs undergo age-dependent compositional remodeling, with Thy1 identified as a key biomarker progressively declining with donor aging. Functional validation confirmed Thy1's critical role in mediating apoV osteoinductive and anti-adipogenic capacities. Engineered Thy1-enriched apoVs, produced through magnetic-activated sorting and protein corona technology, significantly enhanced osteogenesis and suppressed adipogenesis in recipient MSCs by activating the Thy1-ERK-TAZ signaling axis. In aged mouse models, these engineered apoVs restored trabecular bone mass, reduced marrow adipose tissue, and ameliorated systemic lipid metabolism disorders.
conclusionsThis work establishes Thy1 as a functional biomarker for aging-related apoV heterogeneity and demonstrates that engineered Thy1-enriched apoVs represent a clinically scalable therapeutic approach for senile bone-fat imbalance. The identified Thy1-ERK-TAZ mechanism provides a tunable platform for developing extracellular vesicle-based interventions against age-related metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.